Page last updated: 2024-12-07

digoxigenin-mono(digitoxoside)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Digoxigenin-mono(digitoxoside) is a derivative of digoxin, a cardiac glycoside that is widely used in the treatment of heart failure. It is synthesized by enzymatic hydrolysis of digoxin, and it is known to have similar pharmacological effects to digoxin, such as increasing cardiac contractility and slowing heart rate. However, it is believed to have a shorter half-life and a more rapid onset of action than digoxin. Digoxigenin-mono(digitoxoside) is a potent inhibitor of Na+/K+-ATPase, the enzyme responsible for maintaining the sodium-potassium gradient across cell membranes. This inhibition leads to an increase in intracellular calcium concentration, which in turn leads to increased cardiac contractility. Digoxigenin-mono(digitoxoside) is also known to have effects on the nervous system, including the reduction of sympathetic nervous system activity. The study of digoxigenin-mono(digitoxoside) is of interest because it may have potential therapeutic benefits in the treatment of heart failure, as well as other conditions such as atrial fibrillation. Research is ongoing to investigate the safety and efficacy of this compound.'

digoxigenin monodigitoxoside : A steroid saponin that consists of digoxigenin having a digitoxosyl residue attached at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID93001
CHEMBL ID1150
CHEBI ID63496
SCHEMBL ID2729872
MeSH IDM0069254

Synonyms (23)

Synonym
1IGJ
digoxigenin-mono(digitoxoside)
chebi:63496 ,
CHEMBL1150
5352-63-6
3-[(3s,5r,8r,9s,10s,12r,13s,14s,17r)-3-[(2r,4s,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one
digoxigenin monodigitoxoside
card-20(22)-enolide, 3-((2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
digoxigeninmonodigitoxoside
monodigitoxosyldigoxigenin
(3beta,5beta,12beta)-3-[(2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy]-12,14-dihydroxycard-20(22)-enolide
3beta-(beta-d-ribo-2,6-dideoxy-hexopyranosyloxy)-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolide
SCHEMBL2729872
digoxigenin mono-digitoside
Q27132657
MS-29659
TP62PJG6J3
digoxin impurity d [ep impurity]
3.beta.-(2,6-dideoxy-.beta.-d-ribo-hexopyranosyloxy)-12.beta.,14-dihydroxy-5.beta.-card-20(22)-enolide
CS-0356763
DTXSID901309084
HY-145154
AKOS040755020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
cardenolide glycosideAny member of the class of cardenolides with glycosyl residues attached to position 3.
digitoxoside
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
steroid saponinAny saponin derived from a hydroxysteroid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain C, IGG2A-KAPPA 26-10 FAB (LIGHT CHAIN)Mus musculus (house mouse)Kd0.00010.00010.00010.0001AID977611
Chain D, IGG2A-KAPPA 26-10 FAB (HEAVY CHAIN)Mus musculus (house mouse)Kd0.00010.00010.00010.0001AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1993Proceedings of the National Academy of Sciences of the United States of America, Nov-01, Volume: 90, Issue:21
26-10 Fab-digoxin complex: affinity and specificity due to surface complementarity.
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127479Binding affinity against murine monoclonal antibody (mAb)-40-502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (40.00)18.7374
1990's3 (30.00)18.2507
2000's1 (10.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]